Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 14/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | CASP9 | P55211 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12011115 | 0.95 | PTGER4 (0.52) | PTGER4CYP1A2CYP2D6SMN1; SMN2RECQL | |
| SCHEMBL10058539 | 0.94 | PTGER4 (0.54) | PTGER4CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL10058496 | 0.91 | PTGER4 (0.46) | PTGER4CYP1A2CYP2D6SMN1; SMN2RECQL | |
| SCHEMBL10058518 | 0.90 | PTGER4 (0.49) | PTGER4CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL9947684 | 0.90 | PTGER4 (0.57) | PTGER4CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL10058549 | 0.90 | PTGER4 (0.47) | PTGER4CYP1A2CYP2D6SMN1; SMN2RECQL | |
| SCHEMBL10058534 | 0.89 | PTGER4 (0.48) | PTGER4CYP1A2CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL9606644 | 0.89 | PTGER4 (0.46) | PTGER4CYP1A2CYP2D6SMN1; SMN2RECQL | |
| SCHEMBL9606636 | 0.89 | PTGER4 (0.59) | PTGER4CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL10058536 | 0.88 | PTGER4 (0.44) | PTGER4CYP1A2CYP2D6SMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207213-B2 | Benzoisoindole derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207213-B2 | Benzoisoindole derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRK1, OPRD1, OPRL1 | PTGER4 106/4885CYP1A2 41/4885CYP2D6 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.